Grant: Collaborative Research and Development Grants
University of Victoria
$38,283.00
Proteomics-based Direct Diagnosis
FY 2018-19
Summary
This NSERC Collaborative and Research Development Grant proposal represents an exciting collaborative opportunity between a Canadian biotechnology company, Vancouver Island Antibodies Ltd., that specializes in SISCAPAr immuno-mass spectrometry-based diagnostic technology, a Canadian university-based research team (Cameron laboratory) located at the University of Victoria with novel expertise in spirochete biology and diagnostic antigen discovery and development, and a research team at the Institute of Tropical Medicine in Antwerp, Belgium (Kenyon laboratory) with expertise in proteomics and biomarker discovery. This proposal focuses on the measurement of microbial biomarkers in urine and plasma samples, using novel technology, to enable direct diagnosis of active infections. As a result of the combined expertise of the Cameron and Kenyon labs within the field of spirochete research, we will focus upon four economically important and globally prevalent infections: syphilis (caused by Treponema pallidum subspecies pallidum), yaws (caused by Treponema pallidum subspecies pertenue), leptospirosis (caused by Leptospira species) and Lyme disease (caused by Borrelia burgdorferi). Unlike other diagnostic methods, SISCAPArtechnology measures antigens from the infecting organism thus improving on current sub-standard diagnostics. The method involves three main steps: (1) identification of unique spirochete proteins that are expressed at a sufficient levels during infection, subsequent selection of key proteotypic peptides as protein surrogates and derivation of affinity-purified antibodies specific for these peptides; (2) testing of the antibodies for their ability to enrich the surrogate peptides and analysis of their lower limits of detection by mass spectrometry and (3) testing of samples (urine and plasma) for diagnostic identification of active infection. The project will have significant economic benefit for Canada through training of highly skilled workers, enhancement of research and development and the establishment of a diagnostic platform that can successfully diagnose diseases that have a global distribution, are economically relevant and have historically been difficult to diagnose.
Program
Collaborative Research and Development Grants
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
520749-2017
Name nom
Cameron, Caroline
Department département
Biochemistry and Microbiology
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2017
Award amount
38283
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Partie
1
Nb partie
1
Application title
Proteomics-based Direct Diagnosis
Keyword
NSERC
Application summary
This NSERC Collaborative and Research Development Grant proposal represents an exciting collaborative opportunity between a Canadian biotechnology company, Vancouver Island Antibodies Ltd., that specializes in SISCAPAr immuno-mass spectrometry-based diagnostic technology, a Canadian university-based research team (Cameron laboratory) located at the University of Victoria with novel expertise in spirochete biology and diagnostic antigen discovery and development, and a research team at the Institute of Tropical Medicine in Antwerp, Belgium (Kenyon laboratory) with expertise in proteomics and biomarker discovery. This proposal focuses on the measurement of microbial biomarkers in urine and plasma samples, using novel technology, to enable direct diagnosis of active infections. As a result of the combined expertise of the Cameron and Kenyon labs within the field of spirochete research, we will focus upon four economically important and globally prevalent infections: syphilis (caused by Treponema pallidum subspecies pallidum), yaws (caused by Treponema pallidum subspecies pertenue), leptospirosis (caused by Leptospira species) and Lyme disease (caused by Borrelia burgdorferi). Unlike other diagnostic methods, SISCAPArtechnology measures antigens from the infecting organism thus improving on current sub-standard diagnostics. The method involves three main steps: (1) identification of unique spirochete proteins that are expressed at a sufficient levels during infection, subsequent selection of key proteotypic peptides as protein surrogates and derivation of affinity-purified antibodies specific for these peptides; (2) testing of the antibodies for their ability to enrich the surrogate peptides and analysis of their lower limits of detection by mass spectrometry and (3) testing of samples (urine and plasma) for diagnostic identification of active infection. The project will have significant economic benefit for Canada through training of highly skilled workers, enhancement of research and development and the establishment of a diagnostic platform that can successfully diagnose diseases that have a global distribution, are economically relevant and have historically been difficult to diagnose.